maintained at day7 after LPS injection. Comprehensive cytokine assay (ELISA) showed that more than 2 folds of down-regulation of both inflammatory promoting cytokines (IL-1 alpha, IL-6) and chemokines (CCL3, CXCL1) were observed in epididymitis model of IDO KO mice compared with WT mice. On the other hand, more than 1.5 folds of upregulation of inflammatory inhibiting cytokines (IL-4, IL-10) were observed in epididymitis model of IDO KO mice. The peak expression of IL-1 alpha, IL-6, CCL3 and CXCL1 were at day1 and that of IL-4 was at day3. The expression of IL-10 increased in time dependent manner. Same results were introduced from separate quantitative analysis and immunohistochemical staining. After treatment of IDO inhibition and LPS, IL-1 alpha, IL-6, CCL3 and CXCL1 were significantly downregulated anytime in time series compared with WT mice using ELISA method (p<0.05). IL-4 and IL-10 were significantly up-regulated anytime in time series compared with WT mice (p<0.05). In the group of IDO inhibition, epididymal ductal structure was maintained at day7 after LPS injection and little invasion of inflammatory cells were observed anytime in time series.
INTRODUCTION AND OBJECTIVES: Dysfunctional voiding associated with chronic prostatic inflammation is considered to be caused by sensitization of primary sensory neurons innervating lower urinary tract. Published research implicates pro-inflammatory cytokines as major player in the neural sensitization and the progression of prostatitis. Therefore, we investigated the expression of cytokines and chemokines in dorsal root ganglia (DRG) from the lumbosacral region in rat model of non-bacterial prostatitis.
METHODS: Intraprostatic injection of formalin (50mL) or saline (sham) was performed in three month-old male Sprague-Dawley rats to induce prostatitis(n¼3). 12 hour night time urination pattern were noted a day before injection and 7 days later. Lumbosacral L6-S1 and cervical (C4) DRG were isolated from the sacrificed animals on the 7th day for multiplex analysis of 27 cytokines, chemokines and growth factors using a MILLIPLEX MAP Rat Cytokine/Chemokine Panel kit. Results are expressed as pg/mg of total protein RESULTS: The expression of IFN-g, CXCL-10, VEGF and EGF was signficantly elevated in the L6-S1 DRG relative to the C4 DRG of either group(*p<0.05). Expression of CXC chemokines (CXCL-1, CXCL-2, CXCL-5), CC chemokines (CCL2, CCL3, CCL5), leptin, IL-2, IL-13 and IL-17A was only elevated in L6-S1 DRG relative to C4 DRG of sham group (#p<0.05). Frequent urination and reduced voided volume in the prostatitis group was also associated with substantial but insignficant increase in the production of CXCL-1 (p¼0.06), CCL2 and leptin in the C4 DRG relative to that of the sham group.
CONCLUSIONS: Dysfunctional voiding secondary to prostatic inflammation was linked to the dramatic overproduction of inflammatory mediators in L6-S1 DRG capable of inducing phenotypic changes in micturition reflex pathways. Since cervical DRG is not directly innervated by the axons of afferent neurons from prostate and bladder, therefore, sustantial production of leptin, CXCL-1 and CCL2 in the cervical DRG may be humorally mediated in prostatitis to suggest a role for neurohumoral interaction in the evolution of prostatitis into a regional pain syndrome. Stephen Murphy, Jonathan Anker, Anthony Schaeffer, Praveen Thumbikat*, Chicago, IL INTRODUCTION AND OBJECTIVES: Gram-positive bacterial strains comprise the most common isolates found in both healthy and CPPS patient samples. The role of these bacteria in development and maintenance of pain in CPPS is unknown METHODS: Gram-positive bacteria were isolated from the prostates, i. e. bacteria count was 1 log greater in the EPS or VB3 than that in the VB1 and VB2, of three CPPS patients (pain inducers, PI) and one from a healthy volunteer (non-pain inducer, NPI). The bacteria were inoculated intra-urethrally in two genetic mouse backgrounds and analyzed for their ability to induce tactile allodynia and to colonize the murine prostate.
RESULTS: PI strains (Staphylococcus haemolyticus 2551, Enterococcus faecalis 427 and Staphylococcus epidermidis 7244) were capable of inducing and maintaining robust tactile allodynia responses (200% increase above baseline) for 28 days initiating at day 7 postinfection in NOD/ShiLtJ mice. Conversely the healthy subject derived strain (Staphylococcus epidermidis NPI) demonstrated no significant pain responses above baseline at any time-point examined (Days 7, 14, 21, 28) . Intra-urethral inoculation of any of the four bacterial strains into C57BL/6 mice did not induce significant increases in pain responses above baseline. In vitro adherence and invasion assays revealed no significant difference between strains to invade WPMY or RWPE-1 cells. E. faecalis 427 demonstrated a reduced capacity for intracellular proliferation in WPMY but not RWPE-1 cells compared to the other strains. In vivo, colony counts were also performed on prostate tissues removed from both NOD/ShiLtJ and C57BL/6 mice at day 28 post-infection. All bacterial strains colonized equally well comparing within mouse background including NPI. Significant differences were observed however when comparing the bacterial loads of NOD/ShiLtJ and C57BL/6 mice.
CONCLUSIONS: Gram-positive isolates from the prostates of CPPS patients showed dramatically enhanced ability to induce tactile allodynia compared to taxonomically similar gram-positive strain isolated from a healthy control subject. Pain responses were shown to be dependent on the genetic background of the host and not on in vivo colonization differences between strains. All four strains demonstrated similar growth, invasion and proliferation responses in vitro, strongly implicating host:pathogen interactions in development of pain.
Source of Funding: NIH R01DK094898, R01DK108127.
MP11-08 REASSESMENT OF NON-TRADITIONAL UROPATHOGENS IN CHRONIC PELVIC PAIN SYNDROME (CP/CPPS)
Daniel Mazur, Jonathan Anker, Stephen Murphy, Anthony Schaeffer, Praveen Thumbikat*, Chicago, IL INTRODUCTION AND OBJECTIVES: Localization of traditional uropathogenic bacteria to the prostate has been reported in up to 8% of Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e139 patients with CP/CPPS and in healthy controls. However, the frequency and significance of non-pathogenic bacteria have been highly variable. METHODS: We retrospectively reviewed prostate localization cultures done at our institution from 05/2010 to 11/2014 and the associated patient clinical information. Cultures were considered to be localized to the prostate if bacteria count was 1 log greater in the EPS or VB3 than that in the VB1 and VB2 (criteria 1), or 1 log greater than only that in the VB2 (criteria 2). Bacteria were analyzed for their ability to induce inflammation using THP1-Blue cells reporting NFkB expression.
RESULTS: Using criteria 1, 14% (20 of 146) of patients with the diagnosis of CP/CPPS had localizing cultures all performed by (AJS). A total of 28 bacteria, all gram-positive, localized to their prostates. Using criteria 2, the localizing population included patients seen by other urologists and with 1 of 3 diagnoses: CP/CPPS (group 1, 37 patients), elevated PSA with no pelvic pain (group 2, 12 patients), and category II chronic bacterial prostatitis (CBP) or recurrent UTIs (group 3, 15 patients). Gram-positive bacteria comprised 100% of group 1 localizations, and 92% of group 2, while group 3 was 27% gram-negative. A high NFkB response was noted in 20%, 9%, and 42% of bacteria in groups 1, 2, and 3, respectively. While 100% of gram-negative organisms induced a high NFkB response, there was a subgroup of gram-positives (11% of E. faecalis, 13% of S. haemolyticus, 19% of S. epidermidis; 12 total) that also induced a high response. 100% and 83% of patients with bacteria in this subgroup reported pain and voiding complaints, respectively, compared to 66% and 69% of patients with low NFkB inducing gram-positive prostate bacteria.
CONCLUSIONS: Traditional gram-negative uropathogenic bacteria with high inflammatory response were prevalent among patients with CBP or UTIs. A subset of gram-positive bacteria from patients with CP/CPPS also showed a high inflammatory response and association with more pain and voiding complaints. A subset of traditional non-uropathogenic bacteria may contribute to inflammation and symptoms in patients with CP/CPPS. 
MP11-09 NEXT-GENERATION SEQUENCING OF CHRONIC PROSTATITIS: PRELIMINARY RESULTS OF COMPREHENSIVE SPECIES LEVEL DESCRIPTION IN 212 MEN WITH PELVIC PAIN
Eugene Park*, Richmond, VA INTRODUCTION AND OBJECTIVES: Clinical management of chronic prostatitis is difficult owing to inaccurate diagnostic tests, antimicrobial resistance, and a high rate of recurrence. Recent studies showed that routine cultures fail to identify up to 67% of pathogens, and less than 10% of patients with pelvic pain have a positive culture. Nextgeneration sequencing (NGS) provides a complete and accurate description of the composition of the urinary tract microbiome, and may be of value in dealing with the clinical challenge of pelvic pain and chronic prostatitis.
METHODS: We undertook a community-based observational study of 212 men with pelvic pain and other symptoms of chronic prostatitis; most specimens were obtained after prostatic massage. Urines were analyzed using a multi-amplicon, multi-locus method on the Ion Torrent PGM instrument. NGS was used to describe the complete microbiome, including presumptive pathogens, fungi, and antimicrobial resistance genes.
RESULTS: Bacteria can be detected at 20,000 genomic equivalents and across orders of magnitude in range. A significant number of bacteria were found in 75% of samples, with a mean of 2 bacteria per sample (range, 0-7). Gram-positive anaerobes were found in greatest abundance (60% of samples), including Enterococcus faecalis (30%) and Escherichia coli (25%), significantly greater than the 10% abundance of Enterococcus species previously reported with routine cultures from men with possible prostatitis. Co-infection by Enterococcus faecium and Enterococcus faecalis was common, possibly resulting in formation of a tenacious treatment-resistant biofilm. Antimicrobial resistance to beta-lactams was highest at 35% of samples.
CONCLUSIONS: This preliminary study showed that nextgeneration DNA sequencing of urine after prostatic massage identified numerous clinically-relevant bacteria that would likely have been missed using traditional urine culture methods, and showed that chronic prostatitis is often polymicrobial. The presence of significant numbers of bacteria in 75% of the patients suggests that more patients suffer from the bacterial form of chronic prostatitis than previously estimated. NGS testing may be useful in distinguishing chronic bacterial and abacterial prostatitis.
Source of Funding: None

MP11-10 CLINICAL PHARMACOKINETICS OF BETA-LACTAM ANTIBIOTICS IN PROSTATE TISSUE, AND DOSING CONSIDERATIONS FOR PROSTATITIS BASED ON SITE-SPECIFIC PHARMACODYNAMICS
Kogenta Nakamura*, Nagakute, Japan; Kazuro Ikawa, Hiroshima, Japan; Ikuo Kobayashi, Genya Nishikawa, Keishi Kajikawa, Yoshiharu Kato, Masahito Watanabe, Nagakute, Japan; Motoi Tobiume, Owariasahi, Japan; Kenji Mitsui, Masahiro Narushima, Tokoname, Japan; Kent Kanao, Nagakute, Japan; Norifumi Morikawa, Hiroshima, Japan; Makoto Sumitomo, Nagakute, Japan INTRODUCTION AND OBJECTIVES: Piperacillin-tazobactam (8:1) and flomoxef have activities also against Enterobacteriaceae producing extended-spectrum beta-lactamases. These beta-lactam antibiotics are a therapeutic option for bacterial prostatitis and antibacterial prophylaxis in prostatic surgery. However, their clinical pharmacokinetics in prostate tissue and pharmacodynamics at the site of action had been unclear. This study thus examined, for the first time, the clinical pharmacokinetics of piperacillin-tazobactam and flomoxef in prostate tissue, and estimated their pharmacodynamic target attainment at this site.
METHODS: Piperacillin-tazobactam (total dose of 2.25 g or 4.5 g) or flomoxef (0.5 g or 1 g) was intravenously administered to 101 patients with benign prostatic hypertrophy prior to TURP. Venous blood and prostate tissue samples were collected 0.5e5 h after starting a 0.5-h infusion. Drug concentrations were measured using high-performance liquid chromatography, analyzed using a three-compartment population pharmacokinetic model, and used to estimate the probability of attaining the bactericidal targets (time above the minimum inhibitory concentration [MIC] for bacteria, 50% for piperacillin and 70% for flomoxef).
RESULTS: Both beta-lactams penetrated similarly into prostate tissue, independently of the dose, with mean prostate tissue/plasma ratios of 0.38e0.49 (maximum drug concentration) and 0.36e0.56 (area under drug concentration-time curve). Tazobactam showed similar pharmacokinetic profile with piperacillin. With this medium degree of penetration, the usual dosages of piperacillin-tazobactam 4.5 g three times daily and flomoxef 1 g twice daily (0.5-h infusions) achieved a favorable target-attainment probability of 91.3e94.0%, in prostate tissue, against clinical isolate populations of Escherichia coli and Klebsiella species (the two major causative bacteria in prostatitis). The prostatic pharmacodynamic-based breakpoint MIC (the highest MIC at which the target-attainment probability in prostate tissue was >90%) was 0.5 mg/L for piperacillin-tazobactam 2.25 g twice daily and 0.25 mg/ L for flomoxef 1 g three times daily.
CONCLUSIONS: This study revealed the clinical pharmacokinetics of piperacillin-tazobactam and flomoxef in prostate tissue. The results on the site-specific pharmacodynamic target attainment should rationalize and optimize their dosages for prostatitis especially with Enterobacteriaceae producing extended-spectrum beta-lactamases.
